-
Lancet (London, England) Dec 2017Measles is a highly contagious disease that results from infection with measles virus and is still responsible for more than 100 000 deaths every year, down from more... (Review)
Review
Measles is a highly contagious disease that results from infection with measles virus and is still responsible for more than 100 000 deaths every year, down from more than 2 million deaths annually before the introduction and widespread use of measles vaccine. Measles virus is transmitted by the respiratory route and illness begins with fever, cough, coryza, and conjunctivitis followed by a characteristic rash. Complications of measles affect most organ systems, with pneumonia accounting for most measles-associated morbidity and mortality. The management of patients with measles includes provision of vitamin A. Measles is best prevented through vaccination, and the major reductions in measles incidence and mortality have renewed interest in regional elimination and global eradication. However, urgent efforts are needed to increase stagnating global coverage with two doses of measles vaccine through advocacy, education, and the strengthening of routine immunisation systems. Use of combined measles-rubella vaccines provides an opportunity to eliminate rubella and congenital rubella syndrome. Ongoing research efforts, including the development of point-of-care diagnostics and microneedle patches, will facilitate progress towards measles elimination and eradication.
Topics: Disease Eradication; Global Health; Humans; Measles; Measles Vaccine; Measles virus
PubMed: 28673424
DOI: 10.1016/S0140-6736(17)31463-0 -
Viral Immunology Mar 2018Measles remains an important cause of child morbidity and mortality worldwide despite the availability of a safe and efficacious vaccine. The current measles virus (MeV)... (Review)
Review
Measles remains an important cause of child morbidity and mortality worldwide despite the availability of a safe and efficacious vaccine. The current measles virus (MeV) vaccine was developed empirically by attenuation of wild-type (WT) MeV by in vitro passage in human and chicken cells and licensed in 1963. Additional passages led to further attenuation and the successful vaccine strains in widespread use today. Attenuation is associated with decreased replication in lymphoid tissue, but the molecular basis for this restriction has not been identified. The immune response is age dependent, inhibited by maternal antibody (Ab) and involves induction of both Ab and T cell responses that resemble the responses to WT MeV infection, but are lower in magnitude. Protective immunity is correlated with levels of neutralizing Ab, but the actual immunologic determinants of protection are not known. Because measles is highly transmissible, control requires high levels of population immunity. Delivery of the two doses of vaccine needed to achieve >90% immunity is accomplished by routine immunization of infants at 9-15 months of age followed by a second dose delivered before school entry or by periodic mass vaccination campaigns. Because delivery by injection creates hurdles to sustained high coverage, there are efforts to deliver MeV vaccine by inhalation. In addition, the safety record for the vaccine combined with advances in reverse genetics for negative strand viruses has expanded proposed uses for recombinant versions of measles vaccine as vectors for immunization against other infections and as oncolytic agents for a variety of tumors.
Topics: Animals; Antibodies, Neutralizing; Antibodies, Viral; Disease Transmission, Infectious; Drug Discovery; Humans; Immunization Schedule; Measles; Measles Vaccine; Measles virus; Serial Passage; Technology, Pharmaceutical; Vaccines, Attenuated
PubMed: 29256824
DOI: 10.1089/vim.2017.0143 -
Cleveland Clinic Journal of Medicine Jun 2019Although a safe and effective vaccine has been available for over 6 decades, vaccine hesitancy in the United States and social and political unrest globally have led to... (Review)
Review
Although a safe and effective vaccine has been available for over 6 decades, vaccine hesitancy in the United States and social and political unrest globally have led to undervaccination. As a result, in recent months, vaccine control of measles has been threatened with an alarming upswing in measles cases nationally and internationally. Here, we review the disease and its management in view of recent outbreaks.
Topics: Disease Outbreaks; Humans; Measles; Measles Vaccine; United States; Vaccine-Preventable Diseases
PubMed: 31204978
DOI: 10.3949/ccjm.86a.19065 -
Human Vaccines & Immunotherapeutics 2015Measles was an inevitable infection during the human development with substantial degree of morbidity and mortality. The severity of measles virus (MV) infection was... (Review)
Review
Measles was an inevitable infection during the human development with substantial degree of morbidity and mortality. The severity of measles virus (MV) infection was largely contained by the development of a live attenuated vaccine that was introduced into the vaccination programs. However, all efforts to eradicate the disease failed and continued to annually result in significant deaths. The development of molecular biology techniques allowed the rescue of MV from cDNA that enabled important insights into a variety of aspects of the biology of the virus and its pathogenesis. Subsequently these technologies facilitated the development of novel vaccine candidates that induce immunity against measles and other pathogens. Based on the promising prospective, the use of MV as a recombinant vaccine and a therapeutic vector is addressed.
Topics: Drug Carriers; Genetic Vectors; Humans; Measles; Measles Vaccine; Measles virus; Oncolytic Virotherapy; Vaccines, Attenuated; Vaccines, Synthetic
PubMed: 25483511
DOI: 10.4161/hv.34298 -
Vaccine Dec 2023Since 1969, rubella and its harmful effect on fetuses infected in utero can be prevented by rubella vaccine, usually given in combination with measles vaccine. The... (Review)
Review
Since 1969, rubella and its harmful effect on fetuses infected in utero can be prevented by rubella vaccine, usually given in combination with measles vaccine. The rubella vaccine is highly protective both in children and in adults including women intending to become pregnant. Owing to the use of combined measles and rubella vaccines, congenital rubella infection has been eliminated from the Western Hemisphere and nearly all of Europe. Such combined vaccination is now being applied throughout the world, posing the possibility of eventual rubella eradication. The existence of viruses of animals related to rubella does not appear to be a barrier to eradication of the human virus. However, persistent rubella virus in infants infected in utero and of immunosuppressed patients with granulomas may pose a problem for eradication. Nevertheless, this review posits that eradication of rubella is now feasible if routine vaccination of infants and surveillance for chronic infection are correctly applied.
Topics: Child; Infant; Pregnancy; Adult; Humans; Female; Rubella; Rubella Vaccine; Measles; Measles Vaccine; Rubella virus; Vaccination; Measles-Mumps-Rubella Vaccine
PubMed: 37973510
DOI: 10.1016/j.vaccine.2023.11.014 -
The Journal of School Nursing : the... Aug 2019
Topics: Disease Outbreaks; Humans; Immunization Schedule; Measles; Measles Vaccine; School Nursing; United States
PubMed: 31296143
DOI: 10.1177/1059840519856941 -
JAMA Dermatology Dec 2019
Topics: Humans; Measles; Measles Vaccine; Risk Factors; Vaccination
PubMed: 31825476
DOI: 10.1001/jamadermatol.2019.2663 -
American Journal of Respiratory and... Jul 2019
Topics: Humans; Measles; Measles Vaccine
PubMed: 31259630
DOI: 10.1164/rccm.2001P1 -
Medicina 2020
Topics: Anti-Vaccination Movement; Humans; Mass Vaccination; Measles; Measles Vaccine
PubMed: 32044749
DOI: No ID Found -
Human Vaccines & Immunotherapeutics Aug 2023
Topics: Humans; Measles Vaccine; COVID-19
PubMed: 37725096
DOI: 10.1080/21645515.2023.2261195